 | Up a level |
Soubrane, G; Harding, S P; Wolf, S; Weichselberger, A (2009). Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study. Eye, 23(4), pp. 791-800. London: Nature Publishing Group 10.1038/eye.2008.158
Brown, DM; Kaiser, PK; Michels, M; Soubrane, G; Heier, JS; Kim, RY; Sy, JP; Schneider, S; ANCHOR, Study Group (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England journal of medicine NEJM, 355(14), pp. 1432-44. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa062655
Chakravarthy, U; Soubrane, G; Bandello, F; Chong, V; Creuzot-Garcher, C; Korobelnik, J-F; Larsen, M; Monés, J; Pauleikhoff, D; Staurenghi, G; Virgili, G; Wolf, S (2006). Evolving European guidance on the medical management of neovascular age related macular degeneration. British journal of ophthalmology, 90(9), pp. 1188-1196. London: BMJ Publishing Group 10.1136/bjo.2005.082255
